What should you know about uveal melanoma immunotherapy?

Immunotherapy helps the immune system recognise or attack cancer, but uveal melanoma has biological features that make treatment selection highly individual. A specialist may discuss it when disease has spread or when other approaches are unsuitable. The decision can involve eye findings, scans, previous treatment, autoimmune conditions, medicines, and organ function. Immunotherapy is different from local treatments such as plaque brachytherapy or radiotherapy, which target the eye or a defined area.

Give the oncology team a complete medicine list and mention autoimmune disease, organ transplants, inflammatory conditions, and previous immune treatments. Ask how often treatment is given, which blood tests are needed, and how response will be checked. Keep a record of new symptoms between visits. Do not stop prescribed medicines without advice, and contact the team early if you feel unwell because immune-related effects can involve several organs.

Contact the treatment team urgently for severe diarrhoea, persistent vomiting, yellowing of the skin, dark urine, chest pain, breathlessness, severe headache, confusion, widespread rash, or sudden vision changes. Fever, marked weakness, or rapidly worsening symptoms also need prompt advice. These effects are not proof that treatment is working or failing; assessment determines the cause and next step.

Ask why immunotherapy is being considered, what alternatives exist, how your eye and other organs will be monitored, which medicines could interact with treatment, and whom to contact outside clinic hours.